Merck has entered a collaboration with Variational AI, investing up to $349 million to apply cutting-edge generative AI models for designing novel small molecule therapeutics targeting undisclosed indications. The partnership leverages fine-tuned AI platforms trained on Merck’s proprietary datasets to accelerate drug candidate design and optimization. This signifies a growing trend of pharmaceutical companies harnessing advanced AI algorithms to enhance preclinical drug discovery efficiency and output.